雷珠单抗联合黄斑格栅样光凝治疗糖尿病黄斑水肿疗效观察

Effect of Ranibizumab combined with laser photocoagulation for diabetic macular edema

目的观察雷珠单抗联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床疗效。方法将2015年2月至2017年1月确诊为DME患者79例(79眼),按随机数字表法分为2组。观察组40例,采用雷珠单抗联合黄斑格栅样光凝治疗;对照组39例,采用黄斑格栅样光凝治疗,于治疗后3月、6月时,记录2组患眼最佳矫正视力(BCVA)、黄斑中心厚度(CMT)的变化及不良反应的发生情况。结果治疗前,2组患者最佳矫正视力BCVA比较,差异无统计学意义(P>0.05);治疗后3月及6月,观察组BCVA平均值均明显优于对照组,差异有统计学意义(P<0.05)。治疗前,2组患者CMT比较,差异无统计学意义(P>0.05);治疗后3月及6月,观察组CMT平均值均明显优于对照组,差异有统计学意义(P<0.05)。观察组患者5例患者发生不良反应,经处理症状消失,无后遗症。结论雷珠单抗联合黄斑格栅样光凝治疗糖尿病黄斑水肿具有明显改善视力、加快水肿消退,减少复发等作用。

Objetive To investigate the effects and safety of intravitreal injection of ranibizumab combined with macular laser grid photocoagulation for diabetic macular edema. Methods Seventy-nine cases （79 eyes ） of patients with diabetic macular edema collected from January 2015 to February 2017 in our hospital were randomly divided into observation group and control group. The observation group was given ranibizumab injection combined with laser photocoagulation（40 eyes）, and the control group was only given laser photocoagulation（39 eyes）. Macular edema subsiding, central macular thickness （CMT） change and the best corrected visual acuity （BCVA） were compared between the two groups before and 3, 6 months after the treatment. Complications and adverse reactions were observed during follow-up. Results Before the treatment, there were no differences of BCVA and CMT in two groups （ P 〉 0.05 ） . The BCVA in observation group were betterr than that in control group in 3, 6months after the treatment （P〈0.05）. The CMT in observation group were lower than that in control group in 3, 6months after the treatment （P〈0.05）. In the observation group, 5 patients had adverse reactions, and the symptoms disappeared with treatment. Conclusions The intravitreal injection of ranibizumab combined with macular laser grid photocoagulation could obviously improve the vision, decrease edema and decrease recurrent for diabetic macular edema